VP1 is the only structural polypeptide of aphthovirus able to stimulate the production of neutralizing antibody. The region of VP 1 responsible for this activity was located by testing various proteolytic fragments of VP1 for their ability to compete for virus-specific antibodies in serum raised against the intact polypeptide. No antigenic activity could be detected in VP1 fragments isolated from trypsin-treated virus. Controlled digestion revealed that trypsin cleaved VP1 in four places in a preferred order, whereas chymotrypsin cut at a maximum of two sites. The initial cuts by the two proteases were made very close to each other, and in each case resulted in a greatly reduced affinity of the VP1 fragments for virus-specific antibodies in anti-VP1 serum. In contrast, aphthovirus was resistant to Staphylococcus aureus V8 protease, and treatment of isolated VP1 with this protease generated a peptide of tool. wt. 8500 which competed efficiently with virus for antiserum to VP1 and for an absorbed antiviral serum specific for trypsin-sensitive sites. The results indicate that these antisera interact specifically with aphthovirus at a single antigenic determinant located on VP 1 approximately two-thirds of the way along the polypeptide sequence.
INTRODUCTION
The protective humoral response to infection by aphthovirus (foot-and-mouth disease virus) appears to be directed principally against polypeptide VP 1. There are two lines of evidence for this: first, as shown by Bachrach et al. (1975) , Kaaden et al. (1977) and in the accompanying paper (Haresnape & McCahon, 1983) , inoculation of purified VP| into rabbits or pigs results in the production of antibody that can combine with native virus particles and neutralize their infectivity, VP1 being the only polypeptide able to do this. Second, tryptic cleavage of VP1 in type O aphthovirus is associated with a severe loss of both immunizing activity (Rowlands et al., 1971 ; Kaaden et al., 1977) and ability of the virus to be precipitated by antiserum to isolated VP1 (Haresnape & McCahon, 1983) .
The virus determinant recognized by anti-VP1 serum was called the VP1-A antigen by Haresnape & McCahon (1983) , to distinguish it from a second determinant, VP1-B, which is expressed only on 12S subparticles. The purpose of the work described in this paper was to locate the 1-A class of antigenic determinant, and also to explore methods of preparing immunologically active peptides.
The immunochemistry of VP1 has been studied in detail by testing fragments of VP 1 for their ability to stimulate the production of neutralizing antibody. Strohmaier et al. (1982) detected immunizing activity in two non-overlapping peptides of VP1. In each case, a short terminal sequence was essential for this activity, and synthetic peptides containing these sequences have recently been found to possess immunizing activity (Bittle et al., 1982; Pfaff et al., 1982) . It is clear, however, that many factors, other than the presence of antibody-combining ~" Present address: Central Veterinary Laboratory, P.O. Box 527, Lilongwe, Malawi.
0022-1317/83/0000-5592 $02.00 © 1983 SGM sequences, can influence immunogenicity. To test for possible additional determinants on VP 1 we have examined proteolytic fragments of VP1 for antigenic rather than immunogenic activity by measuring their ability to recognize antiviral antibodies present in antiserum to intact VP1 and also in antiserum to native virus that had been absorbed with trypsin-treated virus. The results support a simple interpretation that antibodies specific for trypsin-sensitive sites interact with aphthovirus at a single immunizing determinant located on a region of VP1 which is accessible to several proteases.
METHODS
The origin of the aphthovirus strain used, O1 Pacheco, has been described by Lake et al. (1975) . The virus was grown and purified according to . Protease treatments of virus were done on sucrose gradient fractions containing 50 to 200 ktg/ml virus protein in 0.04 M-sodium phosphate buffer pH 7.6, 0.1 MNaCI. Digestion with trypsin (TPCK-treated; Worthington) was terminated by addition of excess soybean trypsin inhibitor. Chymotrypsin was obtained from Sigma. Protease-treated virus was concentrated by pelleting for 1 h at 50000rev/min at 20°C and samples containing approximately 10~tg protein were analysed by SDSpolyacrylamide gel electrophoresis (Laemmli, 1970) or by electrofocusing [method (i); . For preparation of proteolytic fragments, 400 Ixg virus protein was electrophoresed on a 15 ~ SDS-polyacrylamide gel and eluted from the gel slices as described by Haresnape & McCahon (1983) .
Partial proteolysis of virus proteins with Staphylococcus aureus V8 protease (Miles Laboratories) was carried out as described by . For digestion on a preparative scale, 1.5 Ixg protease per Ixg virus protein was used.
The preparation of antisera and the simultaneous competition radioimmunoassays (RIA) were as described by Haresnape & McCahon (1983) .
RESULTS

Multiple sites of cleavage by trypsin and chymotrypsin
Treatment of aphthovirus with trypsin cleaves VP1 into large and small fragments, VP1L and VP1S. However, chymotrypsin, which attacks the same region of VP1 (Cavanagh et al., 1977) , produced large and small fragments of VP1 (Fig. 1 c) , both of which ran slightly slower on SDS gels than their respective tryptic fragments (Fig. 1 b) . This suggests that trypsin cleaves VP1 at more than one site, and this was confirmed by treating a sample of virus with both proteases. The result (Fig. 1 d) was identical to that obtained with trypsin alone, proving that trypsin cuts VP1 on both sides of the chymotryptic cleavage site.
A sequence of four tryptic cleavages in VP1 was revealed by incubating aphthovirus with low concentrations of trypsin at 4 °C. The mildest treatment yielded a mixture of two large fragments of very similar size, VP1La and VP1Lb, and one small fragment, VP1Sa (Fig. 1 h) . VP 1La and VP 1Sa appeared to be the products of a single cut in VP1, since they were the largest tryptic fragments observed under conditions in which much of the VP 1 remained intact. VP 1La and VP1Lb appeared to arise from successive cleavage events (i.e. cut a followed by cut b) since only one small fragment, VP1Sa, was visible under these conditions. The molecular weight of intact VP1 is known from its amino acid sequence to be 23 840 (Kurz et al., 1981) , considerably less than earlier estimates based on eleetrophoretic mobility in SDS gels. This discrepancy makes it difficult to estimate the sizes of the various forms of VP1L and VP1S from Fig. 1 . However, if it is assumed that the mobility of VP1 and its fragments are proportional to the logarithm of molecular weight, the sizes of VP1La and VP1Sa can be estimated to be approximately 15000 and 8500 respectively.
Incubation with a higher concentration of trypsin ( Fig. 1 g, f) reduced the proportion of VP1La in the mixture of L fragments, and exhaustive trypsin treatment, as in lane (e), produced only VP1Lb. Meanwhile, VP1Sa was slowly cleaved to smaller forms. This occurred in two stages, the first, cut c, producing a fragment, VP1Sc, of intermediate size (lane f), followed by cut d, producing the smallest S fragment, VP1Sd. The routine procedure for trypsin treatment yielded VP1Lb and VPISd as the principal cleavage products. From their apparent molecular weights of 14 500 and 7000 respectively, it can be estimated that trypsin excises a total of protein of mol. wt. 2000 from VP1. 
Location of an immunizing site of FMD
Cleavage of VP1 by limited protease treatment of aphthovirus. Virus was (a) untreated or treated as described in Methods using (b) 36 Ixg/ml trypsin for 30 min at 37 °C, (c) 50 Ixg/ml chymotrypsin for 30 min at 37 °C, (d) chymotrypsin as in (c) followed by trypsin as in (b), (e) trypsin as in (b), (f) 25 p.g/ml trypsin for 30 min at 4 °C, (g) 5 ~tg/ml trypsin for 30 rain at 4 °C or (h) 1 pg/ml trypsin for 30 min at 4 °C. Lanes (i) and (3.) identify in diagrammatic form the various VP1 fragments produced by trypsin and chymotrypsin respectively. The map at the bottom of the figure indicates the likely cleavage sites of (V) trypsin, and (A) chymotrypsin.
A similar study with chymotrypsin revealed that this protease also cuts VP1 at more than one site. Two L fragments, VP1Lx and a slightly smaller form, VP1Ly, can be seen in Fig. t (c) . At higher chymotrypsin concentrations, the proportion of V P I L y was increased in relation to VP1Lx, but only one form of the smaller fragment, VP 1Sx, was found under all conditions (data not shown). VP!Lx and VP1Sx were apparently generated by a single cut since they were the largest fragments produced under conditions in which the majority of VP1 remained intact. Cuts x and y appeared to be located very close to those of trypsin, cuts a and b respectively. Thus, VP1Lx was indistinguishable in size from the 15 000 mol. wt. VP1La and, likewise, VP 1Ly was indistinguishable from the 14500mol. wt. VP1Lb. The difference between these masses represents a peptide of only 4 to 6 amino acid residues, and it would appear, therefore, that the first cut made in VP1 by chymotrypsin was located within a few residues of the first cut made by trypsin. The two small fragments, VP1Sa and VP1Sx, were also very similar in size. The proteolytic activity of the chymotrypsin preparation was not due to contamination with trypsin, since VP1Lx exhibited a lower isoelectric point than did VP1La when compared by . Antigenic activity of VP1 fragments. VP1 and its fragments were eluted from polyacrylamide gels and allowed to compete with radioactively labelled whole virus for antiserum to VPI in a simultaneous competition radioimmunoassay (the test for I-A antigenic sites, described by Haresnape & McCahon, 1983) . (a) Intact VP1 ; (b) residual intact VPI from chymotrypsin-treated virus; (c) VP1L from trypsin-treated virus; (d) VP1S from trypsin-treated virus; (e) VP 1L from chymotrypsin-treated virus; (f) VP1S from chymotrypsin-treated virus. The treatment with chymotrypsin was as in Fig. 1 (c) , and the treatment with trypsin was as in Fig. 1 (b) .
electrofocusing in polyacrylamide gel (data not shown). Possible locations of the proteolytic cleavage sites are shown in the map of VP 1 (Fig. 1, bottom) . Studies of the inhibition of synthesis by pactamycin (data not shown) indicate that the tryptic fragments of VP1 are orientated with VP1L on the NH~-terminal side of VP1S. This confirms that the primary cleavages, a and x, are made in the same region of VP1 as the internal cleavages described by Strohmaier et al. (1982) . The locations of the two slow tryptic cleavages c and d are unknown, although it is likely that one or both of these correspond to the C-terminal tryptic cleavage described by Strohmaier et al. (1982) .
Antigenic activities of VPIL and VPIS
As shown in the accompanying paper (Haresnape & McCahon, 1983) , trypsin completely destroys those sites on aphthovirus that are recognized by antiserum to isolated VP1. These are defined as VP 1-A antigens. Since treatment with chymotrypsin yielded slightly larger VP 1L and VP1S fragments than trypsin (see Fig. 1 ), the effect of chymotrypsin on the VP1-A determinant was investigated. Since some of the virus remained unaltered under these conditions, it was not possible to assay chymotrypsin-modified virus specifically for antigenic activity. Therefore, VP1L and VP1S were isolated from preparations of protease-treated virus by SDSpolyacrylamide gel electrophoresis, eluted from the gel, and assayed by a competition RIA for 1-A antigenic activity, i.e. the ability to inhibit the precipitation of virus by antiserum to VP1. The results are shown in Fig. 2 . The small amount of intact VP 1 remaining after chymotrypsin treatment of the virus gave a strong response (Fig. 2b) , with which the various fragments of VP1 (Fig. 2c to f ) could be compared. The relative molar concentrations of VP1 and VP1L were measured using an R I A specific f6r the trypsin-insensitive VP1-B determinant (Haresnape & McCahon, 1983) . As a control, tryptic fragments of VP1 were also studied. Neither VP1L (Fig.  2c) nor VP1S (Fig. 2d) isolated from trypsin-treated virus possessed any 1-A antigenic activity, even at concentrations up to 200-fold higher than that of intact VP1 required to give a 5 0~ response. The virus used in this experiment had been treated as in Fig. 1 (b) , and its VP1 was therefore predominantly in the form of VP 1Lb and VP 1Sd. The absence of antigenic activity in these fragments is in agreement with the result previously described for trypsin-treated virus (Haresnape & McCahon, 1983) .
In contrast, low but significant levels of antigenic activity were observed for both VP 1L and VP1S isolated from chymotrypsin-treated virus, as shown in Fig. 2(e, f ) respectively. In this experiment the chymotryptic fragments were predominantly in the larger forms, VP1Lx and VP1Sx. For both fragments, the molar concentration required to give a 5 0~ response in the R I A was 100 to 200 times that of intact VP1 required to give the same response. This shows that a single cleavage of VP1 by chymotrypsin greatly reduced its affinity for virus-specific antibodies in anti-VP1 serum. The significance of the residual activity of these fragments is unclear. It is possible that the site on the virus that is recognized by antiserum to VP1 was cleaved into two approximately equal halves by the mild chymotrypsin treatment, each half-site retaining a much reduced affinity for the antibodies. However, mixing the two chymotryptic fragments produced no enhancement of antigenic activity (data not shown).
The effect of the first tryptic cleavage on VP 1-A antigenic activity was studied by preparing VP1L and VP1S from virus that had been trypsin-treated under mild conditions (as in Fig. 1 h) , and testing the fragments in an R I A in the same way as was done for chymotryptic fragments. The VP1L preparation contained approximately equal amounts of the a and b components, whereas the VP 1S preparation consisted only of VP 1Sa. N o antigenic activity was detected in either preparation although the molar concentration of fragment obtained in the R I A was at least 20 times that of intact VPI required to inhibit 50% of binding (data not shown). This showed that a single tryptic cleavage in VP1 produced fragments with a greatly reduced ability (Haresnape & McCahon, 1983 ) in a simultaneous competition radioimmunoassay.
to compete for VP1-A determinants. In this respect, the tryptic VP1L and VP1S preparation resembled those produced by chymotrypsin. Unfortunately, insufficient amounts of the tryptic fragments were available to permit detection of the very low levels of antigenic activities found in the chymotryptic fragments.
S. aureus V8 protease digestion of VP1 produces an active peptide, VPly
Treatment of aphthovirus with bromelain , thermolysin, clostripain or papain (data not shown) cleaves VPI to fragments similar to those generated by trypsin or chymotrypsin. Thus, the region of VP1 containing the 1-A determinant appears to be sensitive to the action of a variety of proteases on the native virus particle. As yet, the only protease that has been found not to attack this region of VP1 is S. aureus V8 protease, and this enzyme was considered a likely candidate for generating VP1 peptides that retain 1-A antigenicity.
Aphthovirus structural polypeptides in SDS solution were therefore subjected to partial digestion with S. aureus protease. The results are shown in Fig. 3 . Aphthovirus is resistant to 1 ~o SDS at 37 °C so that after incubating with S. aureus V8 protease under these conditions, no loss of the major structural polypeptides was detected by SDS-polyacrylamide gel electrophoresis (Fig. 3, lane c) nor was the VP1-A antigenic activity significantly affected (panel c). However, when the solution was first heated to denature the virus protein and then incubated with the protease, complete cleavage of VP1, VP2 and VP3 occurred, resulting in a mixture of peptides less than half the size of the intact polypeptides (lane b). Nevertheless, antigenic activity was little affected by this treatment. Digest (panel b) and control (panel c) elicited similar responses, demonstrating that the digested VP1 was able to combine with all virus-specific antibodies in antiserum to VPI. In order to identify the peptide, or peptides, containing the VP1-A antigen, the digestion was repeated on a preparative scale. A sample of digest was analysed by electrophoresing on a 20% polyacrylamide gel, shown in Fig. 4(d) . The remainder was run in a parallel lane, which was then cut out and the protein eluted and assayed for VP1-A and VP1-B antigenic activities by competition RIA. To ascertain the origin of the peptides, samples of purified VP1, VP2 and VP3 were treated similarly and run in lanes (a), (b) and (c) respectively.
Two major peptides were derived from VP1 (lane a), called VPlct (mol. wt. 5500) and VPly (mol. wt. 8500). The electrophoretic mobility of VPI~t corresponded to slices 9 and 10 in the preparative lane (e) and that of V PI~ to slice 8. VP 1ct was previously described as a peptide that can be resolved by electrofocusing, and that contains the site of a mutation that abolishes VP 1-B antigenic activity Haresnape & McCahon, 1983) . In this experiment, VPlat was identified as the same peptide by its molecular weight and also by the fact that protein eluted from slices 9 and 10 possessed VP1-B antigenic activity (data not shown).
The results of the assays for VP1-A activity are shown in Fig. 4 (e). Each fraction gave a smooth dose-response curve and the inhibition of binding at a single, constant dilution of eluate is given. Peaks of activity were found in the protein eluted from slices 4 and 8. Slice 4 contained residual intact VPI. However, the major peak of antigenic activity was found in slice 8, and appeared to correspond to the largest and most intensely stained VP 1 peptide in lane (a), called VP1 ~. A lower level of activity was also recovered from slice 9. This could not have been due to the VPlct in this fraction, since VPI~t contains none of the tryptic cut sites . The preparation of VPI? extracted from slice 8 was also able to inhibit binding of intact virus to those antibodies in antiviral serum that are directed specifically against trypsin-sensitive antigenic sites (Fig. 5) . This serum was prepared as described by Haresnape & McCahon (1983) by absorbing antiserum raised against native virus particles with an excess of trypsin-treated virus. The peptide was able to compete for at least 80% of the antiviral antibody (Fig. 5) . This observation confirms that the absorbed antiviral serum is specific for the VP1-A antigenic determinant and that the 1-A activity of purified VP 1 is present in an essentially unaltered form in the ~, peptide.
DISCUSSION
Controlled digestion of aphthovirus under conditions that left a substantial proportion of VP 1 intact yielded the largest VP1L and VP1S fragments. Trypsin and chymotrypsin have very different specificities and the fact that the maximum sizes of fragments generated under these conditions by trypsin (V1La and VP1Sa) matched their chymotryptic homologues (VP1Lx and VP 1Sx) strongly supports the view that both pairs of fragments were products of single cleavage events that occurred very close to each other. The drastic reduction in VP1-A antigenicity that we have found to accompany each of these primary cleavages implies that virus-specific antibodies in anti-VPl sera are directed against a single internal determinant on VPI. The importance of this determinant for the immune response to virus infection is discussed in the accompanying paper (Haresnape & McCahon,1983) .
The proteolytic cleavages that destroyed the VP I-A antigen were located approximately twothirds of the way along the polypeptide sequence from the NH2 terminus (Fig. 1) . This lies within the variable region running from residues 130 to 160 (Beck et al., 1983) , which contains several potential tryptic cut sites and is exposed on the surface of the virus particle (Robertson et al., 1983) . All the evidence therefore suggests that VP1-A antigenic activity is confined entirely to the internal immunogenic region described by Strohmaier et al. (1982) . Our failure to detect any antigenic activity in the C-terminal immunogenic region of VP1 deserves some explanation. It seems unlikely that differences between the viruses were important since strains of the same immunological subtype were used in both studies. A second possibility is that the polypeptide fragments produced by cut a or x may not have been the product of a single cleavage, but that an even earlier cleavage occurred, which was located too near to the C terminus of VP1 to be detected by SDS-gel electrophoresis. This explanation can also be rejected, however, since the C-terminal sequence of VPl is rich in basic amino acid residues (Kurz et al., 1981) , and any loss of these would be readily detectable by electrofocusing ; after limited protease treatment of virus as in Fig. 3 , the residual VP1 was found to be indistinguishable in isoelectric point as well as in size (data not shown). We therefore conclude that, of the two immunizing sites on isolated VP1 described by Strohmaier et al. (1982) , the internal site is the most accessible to proteases and is also by far the most effective in stimulating antibody production. This is consistent with the result of Bittle et al. (1982) who found that a peptide containing the internal site was much more immunogenic than the C-terminal peptide.
Antibodies remaining in antiviral serum after absorption with trypsin-treated virus are directed exclusively against the 1-A class of antigenic site (Haresnape & McCahon, 1983 ). This finding is reinforced by our observation that the antigenicaUy active fragment, VP1), produced by digestion of VPI with S. aureus protease, was also able to compete for these antibodies. This shows that few, if any, of the virus determinants that are recognized by this antiviral serum are dependent on tertiary or quaternary protein conformation. Rather, our findings imply that the severe loss of virus immunogenicity on trypsin treatment is due solely to cleavage within a sequence-dependent determinant, VPI-A, which retains antigenic activity in isolated VPI and in peptides of VP1 that contain the determinant.
